Shots:
Vertex to acquire ViaCyte for $320M in cash. The transaction is expected to close in 2022
ViaCyte brings tools, technologies & complementary assets incl. additional human stem cell lines, intellectual property around stem cell differentiation, and GMP manufacturing facilities to accelerate the development of VX-880 & reduce the burden of patients with T1D globally
In an ongoing P-I/II study, VX-880, an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy showed PoC with very encouraging safety and efficacy results for T1D. Under the ViaCyte partnership with CRISPR Therapeutics, the acquisition also gives access to new hypoimmune stem cell assets
Ref: Businesswire| Image: ViaCyte
